The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression

Cancer Cell International

Volumn 6, Issue , 2006, Pages

  Belkaid, Anissa ^a   Currie, Jean Christophe ^a   Desgagnés, Julie ^a   Annabi, Borhane ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; CARRIER PROTEIN; CHLOROGENIC ACID; DEOXYGLUCOSE; GELATINASE A; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT PROTEIN; SPHINGOSINE 1 PHOSPHATE; THIOGLUCOSE;

ADULT; ARTICLE; BRAIN CANCER; CALCIUM MOBILIZATION; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CHEMOPROPHYLAXIS; CHILD; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HYDROLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 33645872700     PISSN: 14752867     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-6-7     Document Type: Article

References (63)

1. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L: Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004, 79:727-747.
2. Stoclet JC, Chataigneau T, Ndiaye M, Oak MH, El Bedoui J, Chataigneau M, Schini-Kerth VB: Vascular protection by dietary polyphenols. Eur J Pharmacol 2004, 500:299-313.
3. Scalbert A, Manach C, Morand C, Remesy C, Jimenez L: Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 2005, 45:287-306.
4. Arts IC, Hollman PC: Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005, 81:317S-325S.
5. Block G, Patterson B, Subar A: Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992, 18:1-30.
6. Lambert JD, Hong J, Yang GY, Liao J, Yang CS: Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr 2005, 81:284S-291S.
7. Kanadaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT: The antitumor activities of flavonoids. In Vivo 2005, 19:895-909.
8. Roudebush P, Davenport DJ, Novotny BJ: The use of nutraceuticals in cancer therapy. Vet Clin North Am Small Anim Pract 2004, 34:249-269.
9. Zhu X, Chen B, Ma M, Luo X, Zhang F, Yao S, Wan Z, Yang D, Hang H: Simultaneous analysis of theanine, chlorogenic acid, purine alkaloids and catechins in tea samples with the help of multi-dimension information of on-line high performance liquid chromatography/ electrospray-mass spectrometry. J Pharm Biomed Anal 2004, 34:695-704.
10. Moyers SB, Kumar NB: Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 2004, 62:204-11.
11. Kazi A, Smith DM, Daniel K, Zhong S, Gupta P, Bosley ME, Dou QP: Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention. In Vivo 2002, 16:397-403.
12. Mori H, Kawabata K, Matsunaga K, Ushida J, Fujii K, Hara A, Tanaka T, Murai H: Chemopreventive effects of coffee bean and rice constituents on colorectal carcinogenesis. Biofactors 2000, 12:101-105.
13. Chiang YM, Chuang DY, Wang SY, Kuo YH, Tsai PW, Shyur LF: Metabolite profiling and chemopreventive bioactivity of plant extracts from Bidens pilosa. J Ethnopharmacol 2004, 95:409-419.
14. Jin UH, Lee JY, Kang SK, Kim JK, Park WH, Kim JG, Moon SK, Kim CH: A phenolic compound, 5-caffeoylquinic acid (chlorogenic acid), is a new type and strong matrix metalloproteinase-9 inhibitor: isolation and identification from methanol extract of Euonymus alatus. Life Sci 2005, 77:2760-2769.
15. Yen WJ, Wang BS, Chang LW, Duh PD: Antioxidant properties of roasted coffee residues. J Agric Food Chem 2005, 53:2658-2663.
16. Krakauer T: The polyphenol chlorogenic acid inhibits staphylococcal exotoxin-induced inflammatory cytokines and chemokines. Immunopharmacol Immunotoxicol 2002, 24:113-119.
17. Herling AW, Burger HJ, Schwab D, Hemmerle H, Below P, Schubert G: Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system. Am J Physiol 1998, 274:G1087-G1093.
18. van Dijk TH, van der Sluijs FH, Wiegman CH, Baller JF, Gustafson LA, Burger HJ, Herling AW, Kuipers F, Meijer AJ, Reijngoud DJ: Acute inhibition of hepatic glucose-6-phosphatase does not affect gluconeogenesis but directs gluconeogenic flux toward glycogen in fasted rats. A pharmacological study with the chlorogenic acid derivative S4048. J Biol Chem 2001, 276:25727-25735.
19. Bandsma RH, Wiegman CH, Herling AW, Burger HJ, ter Harmsel A, Meijer AJ, Romijn JA, Reijngoud DJ, Kuipers F: Acute inhibition of glucose-6-phosphate translocator activity leads to increased de novo lipogenesis and development of hepatic steatosis without affecting VLDL production in rats. Diabetes 2001, 50:2591-2597.
20. Hemmerle H, Burger HJ, Below P, Schubert G, Rippel R, Schindler PW, Paulus E, Herling AW: Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphate translocase. J Med Chem 1997, 40:137-145.
21. Arion WJ, Canfield WK, Ramos FC, Schindler PW, Burger HJ, Hemmerle H, Schubert G, Below P, Herling AW: Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase. Arch Biochem Biophys 1997, 339:315-322.
22. Leuzzi R, Banhegyi G, Kardon T, Marcolongo P, Capecchi PL, Burger HJ, Benedetti A, Fulceri R: Inhibition of microsomal glucose-6-phosphate transport in human neutrophils results in apoptosis: a potential explanation for neutrophil dysfunction in glycogen storage disease type 1b. Blood 2003, 101:2381-2387.
23. Hiraiwa H, Pan CJ, Lin B, Moses SW, Chou JY: Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b. J Biol Chem 1999, 274:5532-5536.
24. Calderwood S, Kilpatrick L, Douglas SD, Freedman M, Smith-Whitley K, Rolland M, Kurtzberg J: Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood 2001, 97:376-382.
25. Beaudet AL, Anderson DC, Michels VV, Arion WJ, Lange AJ: Neutropenia and impaired neutrophil migration in type 1B glycogen storage disease. J Pediatr 1980, 97:906-910.
26. Kilpatrick L, Garty BZ, Lundquist KF, Hunter K, Stanley CA, Baker L, Douglas SD, Korchak HM: Impaired metabolic function and signalling defects in phagocytic cells in glycogen storage disease type 1b. J Clin Invest 1990, 86:196-202.
27. Bashan N, Potashnik R, Peist A, Peleg N, Moran A, Moses SW: Deficient glucose phosphorylation as a possible common denominator and its relation to abnormal leucocyte function, in glycogen storage disease 1b patients. Eur J Pediatr 1993, 152:S44-S48.
28. Korchak HM, Garty BZ, Stanley CA, Baker L, Douglas SD, Kilpatrick L: Impairment of calcium mobilization in phagocytic cells in glycogen storage disease type 1b. Eur J Pediatr 1993, 152:S39-S43.
29. Potashnik R, Moran A, Moses SW, Peleg N, Bashan N: Hexose uptake and transport in polymorphonuclear leukocytes from patients with glycogen storage disease 1b. Pediatr Res 1990, 28:19-23.
30. Chen PY, Csutora P, Veyna-Burke NA, Marchase RB: Glucose-6-phosphate and Ca2+ sequestration are mutually enhanced in microsomes from liver, brain, and heart. Diabetes 1998, 47:874-881.
31. Arion WJ, Canfield WK, Ramos FC, Su ML, Burger HJ, Hemmerle H, Schubert G, Below P, Herling AW: Chlorogenic acid analogue S3483: a potent competitive inhibitor of the hepatic and renal glucose-6-phosphatase systems. Arch Biochem Biophys 1998, 351:279-285.
32. Ghosh A, Cheung YY, Mansfield BC, Chou JY: Brain contains a functional glucose-6-phosphatase complex capable of endogenous glucose production. J Biol Chem 2005, 280:11114-11119.
33. Konishi Y, Kobayashi S: Transepithelial transport of chlorogenic acid, caffeic acid, and their colonic metabolites in intestinal caco-2 cell monolayers. J Agric Food Chem 2004, 52:2518-2526.
34. Annabi B, Lachambre MP, Bousquet-Gagnon N, Page M, Gingras D, Beliveau R: Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MTI-MMP-driven migration in glioblastoma cells. Biochim Biophys Acta 2002, 1542:209-220.
35. Annabi B, Lachambre MP, Bousquet-Gagnon N, Page M, Gingras D, Beliveau R: Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochem J 2001, 353:547-553.
36. An J, Li Y, van De Werve G, Newgard CB: Overexpression of the P46 (T1) translocase component of the glucose-6-phosphatase complex in hepatocytes impairs glycogen accumulation via hydrolysis of glucose 1-phosphate. J Biol Chem 2001, 276:10722-10729.
37. Edsall LC, Spiegel S: Enzymatic measurement of sphingosine-1-phosphate. Anal Biochem 1999, 272:80-86.
38. i-coupled receptors: Role of ERK MAP kinase and phosphatidylinositol 3-kinase β. Cancer Lett 2002, 181:195-204.
39. Van Brocklyn JR, Young N, Roof R: Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells. Cancer Lett 2003, 199:53-60.
40. Young KW, Nahorski SR: Sphingosine 1-phosphate: a Ca2+ release mediator in the balance. Cell Calcium. Cell Calcium 2002, 32:335-341.
41. Gitzelmann R, Bosshard NU: Defective neutrophil and monocyte functions in glycogen storage disease type 1b: a literature review. Eur J Pediatr 1993, 152:S33-S38.
42. Garty BZ, Douglas SD, Danon YL: Immune deficiency in glycogen storage disease type 1B. Isr J Med Sci 1996, 32:1276-1281.
43. Chen LY, Shieh JJ, Lin B, Pan CJ, Gao JL, Murphy PM, Roe TF, Moses S, Ward JM, Lee EJ, Westphal H, Mansfield BC, Chou JY: Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter. Hum Mol Genet 2003, 12:2547-2558.
44. Annabi B, Bouzeghrane M, Moumdjian R, Moghrabi A, Beliveau R: Probing the infiltrating character of brain tumors: inhibition of RhoA/ ROK-mediated CD44 cell surface shedding from glioma cells by the green tea catechin EGCg. J Neurochem 2005, 94:906-916.
45. Baatout S, Jacquet P, Derradji H, Ooms D, Michaux A, Mergeay M: Study of the combined effect of X-irradiation and epigallocatechin-gallate (a tea component) on the growth inhibition and induction of apoptosis in human cancer cell lines. Oncol Rep 2004, 12:159-167.
46. McLaughlin N, Annabi B, Bouzeghrane M, Temme A, Bahary JP, Moumdjian R, Béliveau R: The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate. Brain Research 2006, 1071:1-9.
47. Warburg O, Posener K, Negelein E: The metabolism of cancer cells. Biochem Zeitschr 1934, 152:129-169.
48. Mathupala SP, Rempel A, Pedersen PL: Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001, 276:43407-43412.
49. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ: PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 2004, 24:1411-1431.
50. Zingone A, Seidel J, Aloj L, Caraco C, Vaquero JJ, Jagoda EM, Chou JY, Green MV, Eckelman WC: Monitoring the correction of glycogen storage disease type 1a in a mouse model using [(18)F]FDG and a dedicated animal scanner. Life Sci 2002, 71:1293-1301.
51. Minn H, Kangas L, Knuutila V, Paul R, Sipila H: Determination of 2-fluoro-2-deoxy-D-glucose uptake and ATP level for evaluating drug effects in neoplastic cells. Res Exp Med (Berl) 1991, 191:27-35.
52. Timperley WR: Glycolysis in neuroectodermal tumours. In: Thomas DGT, Graham DI, eds. Brain tumours. Scientific basis, clinical investigation and current therapy. London: Butterworth's; 1980:145-167.
53. Di Chiro G, Brooks RA, Patronas NJ, Bairamian D, Kornblith PL, Smith BH, Mansi L, Barker J: Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol 1984, 15:S138-S146.
54. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC: Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003, 64:227-237.
55. Dwarakanath BS, Jain VK: Modification of the radiation induced damage by 2-deoxy-D-glucose in organ cultures of human cerebral gliomas. Int J Radiat Oncol Biol Phys 1987, 13:741-746.
56. Woodward GE, Hudson MT: The effect of 2-desoxy-D-glucose on glycolysis and respiration of tumor and normal tissues. Cancer Res 1954, 14:599-605.
57. Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, Ravindranath T, Jain V: Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005, 181:507-514.
58. Kang HT, Hwang ES: 2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sci 2006, 78:1392-1399.
59. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005, 65:613-621.
60. Nicasio P, Aguilar-Santamaria L, Aranda E, Ortiz S, Gonzalez M: Hypoglycemic effect and chlorogenic acid content in two Cecropia species. Phytother Res 2005, 19:661-664.
61. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N: Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005, 280:32081-32089.
62. Bandyopadhyay G, Biswas T, Roy KC, Mandal S, Mandal C, Pal BC, Bhattacharya S, Rakshit S, Bhattacharya DK, Chaudhuri U, Konar A, Bandyopadhyay S: Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood 2004, 104-2514-2522.
63. Lee WC, Choi CH, Cha SH, Oh HL, Kim YK: Role of ERK in hydrogen peroxide-induced cell death of human glioma cells. Neurochem Res 2005, 30:263-270.